Occurrence of Canine Parvovirus Type 2c in the United States

DOI Web Site Web Site 被引用文献2件
  • Charles Hong
    Athens Veterinary Diagnostic Laboratory, University of Georgia, Athens, GA
  • Nicola Decaro
    Department of Animal Health and Well-being, Faculty of Veterinary Medicine of Bari, Valenzano (Bari), Italy
  • Costantina Desario
    Department of Animal Health and Well-being, Faculty of Veterinary Medicine of Bari, Valenzano (Bari), Italy
  • Patrick Tanner
    Biological Research and Development, Merial Limited, Athens, GA
  • M. Camila Pardo
    Biological Research and Development, Merial Limited, Athens, GA
  • Susan Sanchez
    Athens Veterinary Diagnostic Laboratory, University of Georgia, Athens, GA
  • Canio Buonavoglia
    Department of Animal Health and Well-being, Faculty of Veterinary Medicine of Bari, Valenzano (Bari), Italy
  • Jeremiah T. Saliki
    Athens Veterinary Diagnostic Laboratory, University of Georgia, Athens, GA

この論文をさがす

説明

<jats:p> Canine parvovirus (CPV) type 2 (CPV-2) emerged around 1978 as a major pathogen of dogs worldwide. In the mid-1980s, the original CPV-2 had evolved and was completely replaced by 2 variants, CPV-2a and CPV-2b. In 2000, a new variant of CPV (named CPV-2c) was detected in Italy and now cocirculates with types 2a and 2b in that country. The CPV-2c has also been reported from single outbreaks in Vietnam and Spain. This study was conducted to determine if CPV-2c occurs in the United States. Thirty-three fecal samples were collected from dogs in 16 states between April 2006 and April 2007 and were tested for CPV using real-time polymerase chain reaction (PCR). Positive samples were further tested using conventional PCR and minor-groove binding TaqMan PCR assays to determine the viral type and to differentiate vaccine strains from field strains. Twenty-seven samples were positive for CPV, 7 of which were CPV-2c from 5 states: Arizona, California, Georgia, Oklahoma, and Texas. Of the 7 isolates, 4 differed from European CPV-2c isolates by 2 additional single-nucleotide mutations at positions 4076 and 4104, the latter of which produces a ThrAla change at residue 440 located near a major antigenic site. The coast-to-coast geographic distribution of the states in which CPV-2c was detected strongly suggests that this new CPV variant is probably widespread in the United States. The continuous evolution of CPV requires that monoclonal antibody-based and nucleic acid-based diagnostic assays should be periodically checked for sensitivity on prevalent CPV strains. </jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ